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Abstract: Background: The Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) considered the benefits 
of pravastatin therapy and provided insights into cognitive decline/disability in older people but follow-up was short. 
Methods: We performed a feasibility study of 300 PROSPER recruits, 7 years after the trial finished. The subject’s 
general practitioner provided basic follow-up data. Telephone contact with participants established cognition/functional 
level. Relatives of those unsuitable for contact were asked to complete postal questionnaires. 
Results: Of 300 participants we established 132 were alive, 135 dead and 33 lost to follow-up. Of 132 survivors data were 
obtained for 78 participants by telephone, 10 participants with GP diagnosis of dementia, and 3 participants whose relative 
provided information. Therefore cognitive function was determined in 69% of survivors and functional ability in 61%. 
Conclusions: It was feasible to perform long-term follow-up of cognition/functional ability in the majority of survivors 
from a large randomised controlled trial. 
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INTRODUCTION 
 Cognitive decline and disability in old age are major 
public health issues, with both having major effects on social 
functioning and quality of life as well as significant health 
and social care costs. The prevalence of dementia rises 
markedly with increasing age, from approximately 1.5% of 
65-69 year olds to 30% in those aged over 90 [1]. The risk of 
physical disability also increases dramatically with 
advancing age, with approximately 13% of the over-80s 
categorised as having a ‘severe’ problem in the UK national 
census [2]. 
 Cognitive decline and disability in older age have many 
common risk factors. Increasingly it is recognised that 
vascular disease is an important and potentially preventable 
contributor to both. The Prospective Study of Pravastatin in 
the Elderly at Risk (PROSPER) [3] aimed to test the benefits 
of pravastatin treatment in an elderly cohort of men and 
women with, or at high risk of developing, cardiovascular 
disease and stroke. This was a randomised controlled trial of 
5804 people aged 70–82 years with a history of, or risk 
factors for, vascular disease who were assigned to 
pravastatin or placebo. Those with a mini mental status exam 
of <24 [4], and therefore likely significant cognitive 
impairment, were excluded. Pravastatin was stopped at the 
end of the trial and the average duration of pravastatin 
therapy was 3.2 years. The primary endpoint was a  
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composite of coronary death, non-fatal myocardial 
infarction, and fatal or non-fatal stroke and a secondary 
endpoint of cognitive function and disability. Pravastatin 
reduced the incidence of the primary endpoint to 408 events 
compared with 473 on placebo (hazard ratio 0·85, 95% CI 
0·74–0·97, p=0·014). However there was no protective effect 
of pravastatin on cognition or activities of daily living 
(ADL) but the duration of follow-up may have been too 
short to demonstrate any benefit. 
 We aimed to establish a methodology for determining 
long-term, post trial, cognitive function and ability to 
perform activities of daily living in PROSPER survivors. 
 If this is feasible we aim to follow-up all the PROSPER 
survivors. The primary objective of this large scale study 
would be to examine the long term effect of Pravastatin. The 
WOSCOPS long-term follow-up [5] demonstrated carry-
over benefit from 5 years of treatment with pravastatin as 
primary prevention for middle-aged men. These benefits 
were still noted 10 years after study completion but it is 
unknown if similar long-term benefits would be seen in the 
elderly. 
 Additionally the observational data from PROSPER has 
shed light on the pathophysiology of cognitive and function 
decline including roles of haemostasis and thrombosis, 
inflammation, and lifestyle issues such as alcohol [6-8]. 
However the utility of these observations are limited due to 
the relatively short period of follow-up and small decrements 
in cognition and function. Extending follow-up beyond the 
study gives opportunity to study predictors of more severe 
cognitive deficit and functional impairment. 
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MATERIALS AND METHODOLOGY 
 We performed a pilot study of 300 Scottish PROSPER 
recruits to establish feasibility of establishing cognitive 
function and activities of daily living in PROSPER 
survivors. 
 A random sample of 300/2,520 of the original Scottish 
PROSPER cohort was selected. This was on average 6 year 
and 10 months after the end of the original PROSPER study. 
This sample was selected using computer generated random 
numbers and was done by the Robertson Centre for 
Biostatistics, Glasgow University, independent of the clinical 
research team. The Robertson Centre for Biostatistics also 
identified participants who died during the original study, or 
who had been identified in record linkage (19
th
 June 2006) as 
deceased after the randomised observation period of the 
study. 
 The subject’s general practitioner (GP) was contacted by 
letter asking them to confirm the subject was alive and 
suitable for contact. It was felt unsuitable to contact elderly 
participants directly because of potential distress to relatives 
in the case of a subject’s death since the last record linkage 
or subject distress because of a pre-existing diagnosis of 
dementia. If the subject could not be contacted the GP was 
asked to say why (e.g. dementia, dysphasia, subject 
preference, withdrawal of consent from PROSPER study) 
and if there was a relative or caregiver who could be 
contacted instead. The GP was also asked if they considered 
the subject had dementia. Lastly the GP was asked to 
provide contact details for the subject or relative and details 
of current medication. If there was no response from the GP 
within 2 weeks this was followed up by a single reminder 
telephone call to the general practice. 
 If the subject was suitable for review a letter was sent to 
the subject offering a telephone interview in one week’s 
time. A contact telephone number was provided to allow 
participants to opt out if they wish, or change the date or 
time of the telephone interview. 
 Telephone contact with the subject involved initial verbal 
consent for the study. The subject was then asked about their 
residence, cohabittees and any formal home care support. 
Current drug treatment was recorded, including use of 
statins. Disability was then assessed by telephone 
administration of the Barthel index [9] and short 
Instrumental Activities of Daily Living questionnaire 
(IADL) [10]. The Barthel index is a commonly used measure 
of disability and Korner-Bitensky at al demonstrated a 
intraclass correlation coefficient of 0.89 when comparing a 
telephone and home assessment of the Barthel index in 366 
individuals [11]. The IADL is made of six sections and the 
intraclass correlation coefficient for each section ranges from 
0.66 to 0.87. The modified Telephone Interview of Cognitive 
Status (TICSm) was also administered to assess cognition. 
This is a 21-item questionnaire with a maximum score of 40 
[12;13] and it is considered further in the discussion. 
 When a subject was not suitable for contact and a relative 
was available a postal questionnaire was sent to the relative. 
This consisted of the short form of the Informant 
Questionnaire on Cognitive decline in the elderly (IQCODE) 
[14], the Barthel index [9] and short IADL questionnaires 
[10]. The IQCODE has been found to have high internal 
reliability in a general population sample (alpha = 0.95) and 
reasonably high test-retest reliability over one year in a 
sample of those with dementia (r = 0.75) [15]. There were 
also questions on the type of residence, formal home care 
support, and any cohabittees. Caregivers or relatives who did 
not return the postal questionnaire within 2 weeks were 
reminded by a single telephone call. 
DATA ANALYSIS AND STATISTICAL METHODS 
 It was estimated, based on Scottish mortality rates, that 
approximately 50% of participants would still be alive at 7 
years after the trial finished. Our previous study experience 
of telephone contact suggested that it should be possible to 
gather cognitive data on around 74% of available 
participants [16]. Therefore we estimated obtaining 
information on 97 in our pilot of 300 PROSPER participants. 
 All-cause mortality was calculated for those not lost to 
follow-up. Cognitive impairment was calculated and defined 
as subject scoring <21 on the TICSm or relative/caregiver 
giving a score of ?3.38 on the IQCODE or subject who the 
GP deemed to have dementia. The cut-off for the IQCDOE 
are validated and established [14]. The cut-off for the TICSm 
is less established but is considered in the discussion. 
 There is no simple cut-off to diagnose disability, 
therefore the change in Barthel and IADL from study 
baseline to pilot study follow-up were analysed as 
continuous variables. Decline in disability was compared 
between placebo and pravastatin groups using linear models 
adjusting for the baseline measure of the variable. A further 
model was fitted adjusting for the known risk factors above. 
Adjusted least square means and standard errors are reported 
for each treatment group and mean differences with 95% 
confidence intervals and p-values are also given. 
 Baseline characteristics were reported comparing the 
PROSPER survivors who developed dementia to survivors 
who did not develop dementia. Continuous variables are 
presented as mean and standard deviation and categorical 
variables are summarised as number and percentages. 
Continuous variables are analysed by two sample t-test and 
categorical variables by Chi-square test or Fisher’s exact test 
as appropriate. The distributions of the baseline variables 
interleukin-6, C-reactive protein and D-dimer were markedly 
skewed and therefore log-transformed. The summary results 
presented for these variables are therefore their geometric 
mean and standard deviation, and the log transformed 
variables were analysed. 
ETHICAL CONSIDERATIONS 
 The PROSPER study participants had consented to long 
term follow-up during the original study and telephone 
contact with the subject involved initial verbal consent for 
the study. The institutional ethics review boards of all 
centres approved the original PROSPER protocol, and all 
participants gave written informed consent. The protocol was 
consistent with the Declaration of Helsinki. 
RESULTS 
 A flow chart of recruitment and data collection is given 
as Fig. (1). Of the 300 Scottish PROSPER participants 
randomly selected, 135 had died and 132 were known to be 
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alive at the time of review, at an average of 6yrs 10 months 
after study completion. 
 Of the 300 participants in our random sample, 
survivorship was established through record linkage and GP 
contact in 267 (89%), therefore we had no information on 
the mortality status of 33 participants. Of the 132 known 
survivors long-term follow-up cognitive function data were 
obtained for 78 participants who had telephone interview, 10 
participants with a GP diagnosis of dementia but no contact 
details for a caregiver, and 3 participants unsuitable for 
personal follow-up for whom their caregiver provided 
questionnaire data. Two of these 3 participants were 
unsuitable for telephone follow-up because of severe 
deafness and one because of dysphasia. The other 3 
participants whose relatives were contacted all had a GP 
diagnosis of dementia but none replied. This gave a total of 
91/132 (69%) survivors in whom long-term cognitive 
outcome could be determined. Functional data was available 
for the 81 subject who had a telephone interview or for 
whom their caregiver provided information; this gave a total 
of 81/132 (61%) survivors in whom both long-term 
functional and cognitive data could be established. 
 GPs were reminded after 14 days if the postal 
questionnaire had not been returned. Many GPs had more 
than one participant in this follow-up study. The GPs of 99 
participants had not responded within 14 days and the GPs of 
89 participants were sent a reminder, the others responding 
before the reminder could be sent out. All but 2 GPs 
responded (4 participants). Although there was an excellent 
response from GPs 33 participants remained untraceable as 
 
Fig. (1). Study flow chart - Recruitment and data collection for the PROSPER study long-term follow-up, 
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GPs told us 23 were no longer listed with them, 6 had been 
untraceable at the end of the original PROSPER study and 
the GPs of 4 participants did not respond despite a reminder. 
 Thirty eight participants who were suitable for a 
telephone interview did not have one. Twenty nine declined; 
17 did so by phoning in advance, 12 did so on day of 
interview. Five did not answer their phone despite repeated 
attempts. We attempted to phone these participants on at 
least three occasions at varying times of day. One participant 
had died recently, 1 had no phone, 1 was deaf (although the 
GP had alerted us to this but felt they could still be 
contacted) and 1 was away from home throughout the study. 
Of the 78 participants who did have a telephone interview 8 
rearranged their appointment by phone as the original time 
given did not suit. 
 Six relatives/caregivers were sent a postal questionnaire. 
Three replied and after 14 days the other three were 
reminded by telephone. One told us they did not wish to  
 
participate and other two did not reply despite the reminder. 
Additionally 10 participants were identified as being 
unsuitable for contact because of dementia but the GP was 
not aware of the nearest relative/caregiver contact details. 
 Although this study was largely designed to consider 
methodology some provisional results were considered. The 
proportion of deaths, over a mean of 10 years follow-up 
(including trial duration of 3.2 years and post-trial follow-up 
period of 6yrs 10 months), was very similar in the original 
PROSPER study placebo and pravastatin groups (Table 1) at 
around 50%. The proportion of those with significant 
cognitive impairment was very similar in the placebo and 
pravastatin groups at around 31%. The baseline 
characteristics of the 28 PROSPER survivors who developed 
significant cognitive impairment were compared with 63 
survivors who did not (Table 2). Cognitive impairment 
associated with older age at baseline (p=0.007). In survivors 
there was a decline in Barthel by approximately 1 point  
 
Table 1. Cognitive Function and Deaths 
 
 Total Placebo Pravastatin 
TICSm <21/40 16/78 6/38  10/40  
IQCODE ? 3.38 2/3 2/3  0/0 
GP diagnosis of dementia 10 6 4 
Total with known significant cognitive impairment  
(of the 91* were alive and contacted directly or via a caregiver and those whose GP diagnosed dementia) 
28/91 (31%) 14/47 (30%) 14/44 (32%) 
Total deceased 
(of the 267 who were not lost to follow-up) 
135/267 (51%) 65/131 (50%) 70/136 (52%) 
*Although 132 participants were potentially contactable 41 did not take part in phone interviews or their caregiver did not respond to questionnaire. 
TICSm = Telephone Interview Cognitive Status (modified). 
IQCODE = Informant Questionnaire on Cognitive decline in the Elderly. 
 
Table 2. Baseline Characteristics of PROSPER Survivors who have Developed Dementia or Significant Cognitive Impairment 
Compared to Survivors who have Not 
 
Baseline Characteristic Alive No Dementia (n=63) Alive with Dementia (n=28) p 
Age (years), mean (SD) 74.0 (3.0) 76.0 (3.6) 0.007 
Gender (male) 29 (46.0%) 11 (39.3%) 0.55 
History of Vascular Disease 30 (47.6%) 16 (57.1%) 0.40 
Diabetes 4 (3.2%) 2 (7.1%) 1.00 
Current Smoker 8 (12.7%) 5 (17.9%) 0.35 
Any alcohol intake 35 (55.6%) 12 (42.9%) 0.26 
Randomised to Pravastatin 30 (47.6%) 14 (50.0%) 0.83 
Education (years), mean (SD) 15.1 (1.4) 14.8 (1.2) 0.44 
SBP (mmHg), mean (SD) 148.7 (20.6) 157.2 (24.7) 0.094 
CRP (geometric mean), (SD) 2.6 (3.4) 2.1 (3.9) 0.50 
IL6 (geometric mean), (SD) 2.1 (1.9) 2.0 (1.7) 0.73 
D-dimer (geometric mean), (SD) 228.8 (1.6) 260.4 (1.7) 0.23 
SBP = systolic blood pressure. 
CRP = C-reactive protein. 
IL6 = Interleukin-6. 
D-dimer = a fibrin degradation protein tested in the blood to help diagnose thrombosis. 
Results of continuous variables are mean (SD) except where stated; categorical variables are summarised as number (%). Continuous variables are analysed by 2 sample t-test (using 
log-transformed data for IL-6 and CRP), and categorical data by Chi-squared or Fisher’s exact test as appropriate. 
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(20-point scale) over the 10 years from study baseline, and 
for IADL a decrease by 1.7 points (14-point scale), with no 
significant differences between the placebo and pravastatin 
groups (Fig. 2). This small decline in function may not be of 
individual clinical significance but will be investigated 
further in the full follow-up study. However van Exel at al 
have shown that a 1 point decrease in Barthel after stroke can 
impact on quality of life [17]. 
 With further time elapsed, and continuing deaths of 
around 8% per annum, we anticipate at 9 years after study 
completion, around 42% (n=2438) of the original cohort of 
5804 will be available for review. If cognitive function can 
be established in 69% and basic and instrumental activities 
of daily living in 61% of these survivors, as in the feasibility 
study, this would give results for 1680 for cognition and 
1487 for activities of daily living. With these numbers we 
would have >80% power (at p=0.05, 2 tailed) to detect a 
difference in proportion of 7% (31 versus 38%) with 
cognitive impairment, between pravastatin and placebo 
groups. We would have the same power to detect 0.14 of a 
SD in change in Barthel or IADL between pravastatin and 
placebo groups. The most conservative estimates of SD of 
change in these variables are with adjustment for baseline, 
age, gender, education, history of vascular disease, diabetes 
mellitus, smoking status, alcohol intake and systolic blood 
pressure; with these adjustments we found the SD of change 
of Barthel to be 0.56 units and for IADL 0.73 units. These 
calculations were done using G*Power 3:1 [18]. 
DISCUSSION 
 We have traced (through the GP) and recontacted a 
subgroup of 300 Scottish participants of the PROSPER 
study, at an average of 6yrs 10 months after completion of 
the randomised controlled trial phase of PROSPER. This 
time-point is at 10 years after entry to PROSPER and 
measurement of study baselines. We found approximately 
50% of the original study sample are now deceased. This is 
in line with our pre-study estimates and if all of the Scottish 
PROSPER participants were followed-up this would equate 
to a cohort of approximately 1,100. We were unable to trace 
33/300 (11%) of our study sample. While any loss to follow-
up is disappointing this level of case-ascertainment 
demonstrates that it is possible, using record linkage and GP 
contact, to ascertain long-term cognitive and ADL outcomes 
for the majority of participants in PROSPER. The long-term 
follow-up of the West of Scotland Coronary Prevention 
Study [19], another large randomised control trial of statin 
therapy, was able to obtain details of cardiac morbidity and 
mortality in 91% of participants but this was from 
hospital/national records only and the participants were not 
approached. 
 The GPs were invariably very helpful in responding to 
our contact although a 14 day reminder phone call was 
needed for 89/300 participant’s GPs. More up-to-date record 
linkage with the General Register Office of Scotland might 
reduce loss to follow-up and it may be possible to use record 
linkage to establish current GP/address. It is our intention to 
have complete up-to-date record linkage for the full follow-
up study. This will also allow further consideration of  
 
mortality including the cause and timing. We did have some 
information on four non-survivors who had dementia 
recorded on their death certificate but as there was only 
partial record linkage in this study we did not include this 
information. We accept that a GP’s criteria for a diagnosis of 
dementia may vary. We had aimed to assess those given a 
GP diagnosis of dementia via postal IQCDOE but for most 
participants in this category a caregiver was not available 
and none of the three caregivers approached responded to 
our questionnaire. 
 Our previous study experience of telephone contact 
suggested that it should be possible to gather cognitive data 
on around 74% of available participants [16]. The acceptance 
rate in this study for telephone interview was similar to our 
previous experience but we are considering how this 
percentage might be increased without pressurising 
participants. In this study we were able to establish data on 
cognition in 69% of those participants who were know to be 
alive and functional ability for 61%. This would equate to 
the ability to follow-up the cognition/function of 670 
Scottish PROSPER participants and about 1,600 participants 
from the full PROSPER cohort. No other long-term follow-
up of a large randomised control trial has attempted to gather 
data directly from very elderly participants, so these data are 
unique and may be useful in planning long-term follow-up of 
other similar cohorts. 
 In contrast obtaining contact details for 
relatives/caregivers and then getting a response proved 
difficult, and this line of enquiry yielded only limited 
additional information. It may be possible to get additional 
information from GPs for those participants who are not 
contactable rather then try to get this through 
relatives/caregivers. 
 We found a prevalence of significant cognitive 
impairment in around 31% of traceable participants. This is 
higher than expected; the EURODEM analysis [1] gives a 
prevalence of dementia at age 80-85 of approximately 11% 
for men and 12.6% for women. This is despite the fact that 
those with known dementia were prevented from entering 
the original PROSPER study. However we have had to use a 
pragmatic definition of significant cognitive impairment that 
included a simple cut-off on the TICSm. We accept that 
cognitive impairment is a spectrum and handling the TICSm 
as a continuous variable may have benefits in improving 
statistical power. However the dichotomisation of scales, 
such as the MMSE, is widely used to simplify the 
presentation and analysis of data in research, and in clinical 
practice to aid diagnosis and ascertain suitability for 
treatment. Our initial plan was to use a cut-off of <27 for the 
TICSm as one of our criteria for dementia. However this led 
to an implausibly high prevalence of dementia in survivors. 
We therefore reviewed our criteria for dementia, in particular 
the cut-off of TICSm to be applied. The TICSm is a 
modification of a validated telephone memory screen; it 
shows a strong correlation (r = 0.94) to the Mini Mental 
Status Examination [12]. When using a 27 point cut-off 
score, the TICS (unmodified) has been claimed to have 99% 
sensitivity and 86% specificity for a dementia diagnosis [13]. 
However there is precedence for considering other  
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cut-points; the MRC Heart Protection Study used a cut-off of 
<22 as indicative of clinically significant cognitive 
impairment [20]. Validation work in the context of 
cerebrovascular disease found a cut-off of <21 for the 
TICSm produced a sensitivity of 92% and a specificity of 
80% [21] for diagnosis of dementia. Ideally we would have 
used a combination of the TICSm and proxy questionnaire in 
all participants; such combined data have been claimed to 
have 100% sensitivity and 83% specificity for dementia 
diagnosis [22]. However we found that obtaining proxy 
information on the PROSPER survivors was not feasible. 
Given the above literature, we suggest that the best estimates 
of dementia risk are based on the most conservative criteria 
that include the cut-off of <21 on TICSm. While these 
 
 
 
 
Fig. (2). Activities of daily living (Barthel index) and instrumental activities of daily living (IADL) during the PROSPER study (baseline to 
month 30) and at long-term review of survivors (7 years after study completion); n=41 subjects allocated to placebo, 40 to pravastatin. 
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figures may still seem high, it is likely that this group of 
participants, with a high burden of vascular disease and vascular 
risk factors, are at particularly high risk of developing both 
Alzheimer disease and vascular dementia [23]. 
 This feasibility study has generated the necessary data to 
enable informed power calculations of the implications of 
revisiting the whole cohort. It appears that with long-term 
follow-up we would have adequate statistical power to expect to 
detect a moderate absolute and relative difference between 
pravastatin and placebo groups, in the risk of clinically 
significant cognitive impairment at 7% and 18% respectively; 
we would also be adequately powered to detect <0.1 point 
difference in change in both Barthel and IADL between the 
pravastatin and placebo groups, equivalent approximately to the 
decline in Barthel seen with 1 year of ageing, and the decline in 
IADL seen with 6 months of ageing in this population. 
 These methods do have a number of limitations. In 
particular loss to follow-up and potential attrition bias are a 
concern. It is possible that we have underestimated the rate of 
dementia and significant cognitive impairment as the 
participants who have been lost to follow-up are perhaps even 
more likely to have been affected. 
 We were able to define groups of PROSPER survivors with 
and without major cognitive impairment. The small number in 
this feasibility study restrict what further exploration can be 
made for risk factors for cognitive impairment; although our 
data showed an expected association of older age at baseline as 
a risk factor for cognitive impairment, other established risk 
factors did not. 
CONCLUSIONS 
 We found that it was feasible to follow-up cognitive 
function and ADL in elderly survivors from the PROSPER 
study, using GP contact followed by telephone subject 
interview. Postal questionnaires to caregivers proved less 
productive. Telephone follow-up of the whole cohort of 
PROSPER participants appears feasible and may determine new 
and novel risk factors for cognitive decline and disability, 
including the long-term effect of a period of treatment with 
pravastatin. 
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